Bone-marrow-derived cells for cardiac stem cell therapy: Safe or still under scrutiny?

被引：15

作者：

Bartunek J. ^{[1
]}

Vanderheyden M. ^{[1
]}

Wijns W. ^{[1
]}

Timmermans F. ^{[2
]}

Vandekerkhove B. ^{[2
]}

Villa A. ^{[3
]}

Sánchez P.L. ^{[4
]}

Arnold R. ^{[3
]}

San Román J.A. ^{[3
]}

Heyndrickx G. ^{[1
]}

Fernandez-Aviles F. ^{[4
]}

机构：

[1] Cardiovascular Center, OLV Ziekenhuis, Aalst

[2] Department of Clinical Chemistry, Microbiology and Immunology, University of Ghent, Ghent

[3] Department of Cardiology, Institute of Heart Sciences (ICICOR), Hospital Clinico Universitario, Valladolid

[4] Department of Cardiovascular Medicine, Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Madrid

来源：

Nature Clinical Practice Cardiovascular Medicine | 2007年 / 4卷 / Suppl 1期

关键词：

D O I：

10.1038/ncpcardio0744

中图分类号：

学科分类号：

摘要：

Cardiac stem cell therapy with bone-marrow-derived stem cells is a promising approach to facilitate myocardial regeneration after acute myocardial infarction or in congestive heart failure. The clinical data currently available seem to indicate that this approach is safe and is not associated with an increase in the number of adverse clinical events; nevertheless, the level of safety confidence is limited because of the small number of patients who have been treated and the absence of long-term clinical follow-up data. In order to establish the clinical safety of cardiac stem cell therapy, it will be necessary to collect additional data from both previous and ongoing clinical trials in subsets of patients relative to their background risk. Several conceptual safety concerns should also be addressed. These concerns relate to a number of operational mechanisms and include biological effects on differentiation, remote homing of transplanted stem cells, progression of atherosclerosis, and arrhythmias. The proactive scrutiny of these phenomena could eventually facilitate the translation of the promise of cardiac regeneration into a safe and effective therapy.

引用

页码：S100 / S105

页数：5

共 33 条

[1]

Givertz M.M., Et al., Clinical aspects of heart failure

[2]

pulmonary edema, high-output failure, Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, pp. 539-568, (2005)

[3]

Strauer B.E., Et al., Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans, Circulation, 106, pp. 1913-1918, (2002)

[4]

Schachinger V., Et al., Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI Trial, J Am Coll Cardiol, 44, pp. 1690-1699, (2004)

[5]

Fernandez-Aviles F., Et al., Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction, Circ Res, 95, pp. 742-748, (2004)

[6]

Wollert K.C., Et al., Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial, Lancet, 364, pp. 141-148, (2004)

[7]

Bartunek J., Et al., Intracoronary injection of CD133<sup>+</sup> enriched bone marrow progenitors promotes cardiac recovery after recent myocardial infarction: Feasibility and safety, Circulation, 112, SUPPL. 1, (2005)

[8]

Janssens S., Et al., Transplantation of autologous bone marrow-derived stern cells in patients with ST-segment elevation myocardial infarction: Double-blind, randomised controlled trial, Lancet, 367, pp. 113-121, (2006)

[9]

Schachinger V., Et al., Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction, N Engl J Med, 355, pp. 1210-1221, (2006)

[10]

Lunde K., Et al., Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction, N Engl J Med, 355, pp. 1199-1209, (2006)

← 1 2 3 4 →